Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I

Fiorella Guadagni, Mario Roselli, Maurizio Cosimelli, Antonella Spila, Francesco Cavaliere, Raffaella Arcuri, Maria Rosaria Abbolito, John W. Greiner, Jeffrey Schlom

Research output: Contribution to journalArticle

Abstract

Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.

Original languageEnglish
JournalDiseases of the Colon and Rectum
Volume37
Issue number2 Supplement
DOIs
Publication statusPublished - Feb 1994

Fingerprint

Carcinoembryonic Antigen
Colorectal Neoplasms
Neoplasm Antigens
Adenoma
Biomarkers
tumor-associated antigen 72
Recurrence
Serum

Keywords

  • Antigen phenotype
  • Colorectal carcinoma
  • Monoclonal antibody
  • Serum marker
  • Tumor antigen

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I. / Guadagni, Fiorella; Roselli, Mario; Cosimelli, Maurizio; Spila, Antonella; Cavaliere, Francesco; Arcuri, Raffaella; Abbolito, Maria Rosaria; Greiner, John W.; Schlom, Jeffrey.

In: Diseases of the Colon and Rectum, Vol. 37, No. 2 Supplement, 02.1994.

Research output: Contribution to journalArticle

Guadagni, Fiorella ; Roselli, Mario ; Cosimelli, Maurizio ; Spila, Antonella ; Cavaliere, Francesco ; Arcuri, Raffaella ; Abbolito, Maria Rosaria ; Greiner, John W. ; Schlom, Jeffrey. / Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I. In: Diseases of the Colon and Rectum. 1994 ; Vol. 37, No. 2 Supplement.
@article{047a9de3632f4dd9b3dc9940d7f2d92c,
title = "Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I",
abstract = "Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.",
keywords = "Antigen phenotype, Colorectal carcinoma, Monoclonal antibody, Serum marker, Tumor antigen",
author = "Fiorella Guadagni and Mario Roselli and Maurizio Cosimelli and Antonella Spila and Francesco Cavaliere and Raffaella Arcuri and Abbolito, {Maria Rosaria} and Greiner, {John W.} and Jeffrey Schlom",
year = "1994",
month = "2",
doi = "10.1007/BF02048426",
language = "English",
volume = "37",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "2 Supplement",

}

TY - JOUR

T1 - Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I

AU - Guadagni, Fiorella

AU - Roselli, Mario

AU - Cosimelli, Maurizio

AU - Spila, Antonella

AU - Cavaliere, Francesco

AU - Arcuri, Raffaella

AU - Abbolito, Maria Rosaria

AU - Greiner, John W.

AU - Schlom, Jeffrey

PY - 1994/2

Y1 - 1994/2

N2 - Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.

AB - Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.

KW - Antigen phenotype

KW - Colorectal carcinoma

KW - Monoclonal antibody

KW - Serum marker

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=0028356739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028356739&partnerID=8YFLogxK

U2 - 10.1007/BF02048426

DO - 10.1007/BF02048426

M3 - Article

C2 - 8313787

AN - SCOPUS:0028356739

VL - 37

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 2 Supplement

ER -